AOC3, amine oxidase copper containing 3, 8639

N. diseases: 106; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Acute vascular insufficiency of intestine (disorder)
0.010 Biomarker disease BEFREE Comparison of the diagnostic values of vascular adhesion protein-1 and intestinal fatty acid-binding protein in the diagnosis of acute mesenteric ischemia. 29600311 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.010 Biomarker group BEFREE Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. 29065711 2019
CUI: C0009763
Disease: Conjunctivitis
Conjunctivitis
0.010 Biomarker disease BEFREE This study investigated the expression of vascular adhesion protein-1 (VAP-1) in SLE patients with conjunctivitis and the relationship between VAP-1 and other proteins in the onset of the disease. 31819770 2019
CUI: C0014060
Disease: Encephalitis, St. Louis
Encephalitis, St. Louis
0.010 Biomarker disease BEFREE This study investigated the expression of vascular adhesion protein-1 (VAP-1) in SLE patients with conjunctivitis and the relationship between VAP-1 and other proteins in the onset of the disease. 31819770 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.010 Biomarker disease BEFREE Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection. 30658395 2019
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.010 AlteredExpression disease BEFREE Serum vascular adhesion protein-1 is up-regulated in hyperglycemia and is associated with incident diabetes negatively. 30022055 2019
CUI: C0024141
Disease: Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic
0.010 Biomarker disease BEFREE This study investigated the expression of vascular adhesion protein-1 (VAP-1) in SLE patients with conjunctivitis and the relationship between VAP-1 and other proteins in the onset of the disease. 31819770 2019
CUI: C0085207
Disease: Gestational Diabetes
Gestational Diabetes
0.010 Biomarker phenotype BEFREE Hence, we think that VAP-1 could be a promising marker for the prediction of gestational diabetes. 31638437 2019
CUI: C0239946
Disease: Fibrosis, Liver
Fibrosis, Liver
0.010 Biomarker disease BEFREE Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection. 30658395 2019
CUI: C0409959
Disease: Osteoarthritis, Knee
Osteoarthritis, Knee
0.010 AlteredExpression disease BEFREE Soluble VAP-1 levels in serum were also lower in radiographically advanced (KL3/4) compared with early KL1/2 knee SKOA patients. 31146362 2019
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic
0.010 Biomarker disease BEFREE In conclusion, VAP-1 plasma concentration, rather than its SSAO activity, may represent a non-invasive biomarker for monitoring fibrogenesis in patients with chronic hepatitis C infection. 30658395 2019
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction
0.010 Biomarker phenotype BEFREE <b>Purpose:</b> VAP-1 plays a crucial role in inflammation, oxidative stress and endothelial dysfunction which are main pathophysiologic mechanisms for gestational diabetes. 31638437 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.010 Biomarker group BEFREE Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. 29065711 2019
CUI: C1623038
Disease: Cirrhosis
Cirrhosis
0.010 Biomarker disease BEFREE According to the receiver operating characteristic (ROC) analysis, a VAP-1 cut-off value of 541 ng/mL predicted histologically confirmed cirrhosis (sensitivity 74%; specificity 72%). 30658395 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.010 Biomarker disease BEFREE VAP-1 is shown to be a biomarker that can be predict invasive potential and clinical outcome in breast cancer. 30160019 2018
CUI: C0007785
Disease: Cerebral Infarction
Cerebral Infarction
0.010 Biomarker disease BEFREE Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. 29175057 2018
CUI: C0014070
Disease: Encephalomyelitis
Encephalomyelitis
0.010 AlteredExpression disease BEFREE Therefore, we investigated the expression of VAP-1 within the CNS vasculature in two focal rat models of experimental autoimmune encephalomyelitis (EAE) mimicking multiple sclerosis (MS). 29716612 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease
0.010 Biomarker disease BEFREE Collectively, our study suggests that the increased expression of VAP-1 is detrimentally associated with the development of GVHD and that the blockade of VAP-1 could be a promising medical modality to combat the acute and chronic variants.-Mukai, S., Ogawa, Y., Kawakami, Y., Mashima, Y., Tsubota, K. Inhibition of vascular adhesion protein-1 for treatment of graft-versus-host disease in mice. 29490166 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.010 GeneticVariation disease BEFREE In addition, these individuals had significantly higher VAP-1 and MDA concentration and lower enzymatic and nonenzymatic antioxidant-status, suggesting that psoriatic patients carrying C allele of AT1R<sub>1166</sub> polymorphism may be more susceptible to cardiovascular disease and myocardial infarction compared with A allele. 30304544 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.010 Biomarker phenotype BEFREE In conclusion, this study suggests that VAP-1 is linked to progression of tumor invasion and metastasis in breast carcinoma. 30160019 2018
CUI: C0030193
Disease: Pain
Pain
0.010 Biomarker phenotype BEFREE Analgesic effects of the novel semicarbazide-sensitive amine oxidase inhibitor SZV 1287 in mouse pain models with neuropathic mechanisms: Involvement of transient receptor potential vanilloid 1 and ankyrin 1 receptors. 29438782 2018
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.010 AlteredExpression disease BEFREE VAP-1 expression is increased in PSC, facilitates adhesion of gut-tropic lymphocytes to liver endothelium in a substrate-dependent manner, and elevated levels of its circulating form predict clinical outcome in patients. 28428344 2018
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.010 Biomarker disease BEFREE VAP-1 is shown to be a biomarker that can be predict invasive potential and clinical outcome in breast cancer. 30160019 2018
CUI: C0742468
Disease: Central nervous system lesion
Central nervous system lesion
0.010 Biomarker disease BEFREE The study indicates that VAP-1 is actively involved in the development of inflammatory CNS lesions. 29716612 2018
CUI: C1176475
Disease: Ductal Carcinoma
Ductal Carcinoma
0.010 Biomarker disease BEFREE Immunohistochemical staining results showed VAP-1 negative or weak staining in normal ducts and ductal carcinoma in situ (DCIS), but these phenotypes were positively associated with a stiffened VAP-1 that presented at the invasive front of the lesion. 30160019 2018